MusclePharm (MSLP) stock price, revenue, and financials

MusclePharm market cap is $38.2 m, and annual revenue was $64.44 m in FY 2020
View Company

$38.2 M

MSLP Mkt cap, 07-May-2021

$64.4 M

MusclePharm Revenue FY, 2020
MusclePharm Gross profit (FY, 2020)19.6 M
MusclePharm Gross profit margin (FY, 2020), %30.4%
MusclePharm Net income (FY, 2020)3.2 M
MusclePharm EBIT (FY, 2020)2.6 M
MusclePharm Cash, 31-Dec-20202 M
MusclePharm EV52.7 M

MusclePharm Revenue

MusclePharm revenue was $64.44 m in FY, 2020

Embed Graph

MusclePharm Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2019FY, 2020

Revenue

17.2m67.1m110.9m177.4m166.9m132.5m102.2m79.7m64.4m

Revenue growth, %

(6%)(21%)

Cost of goods sold

14.8m52.7m77.7m121.4m109.9m88.0m71.7m71.0m44.8m

Gross profit

2.4m14.3m33.2m56.0m56.9m44.5m30.4m8.7m19.6m

Gross profit Margin, %

14%21%30%32%34%34%30%11%30%

Sales and marketing expense

8.4m15.5m28.1m27.0m10.7m9.4m2.5m507.0k

R&D expense

1.1m4.0m4.3m1.9m642.0k893.0k

General and administrative expense

18.6m23.1m47.5m13.4m19.4m15.9m12.1m8.9m7.1m

Operating expense total

18.6m23.1m47.5m75.4m106.9m53.1m37.6m23.8m17.0m

EBIT

(16.2m)(8.7m)(14.3m)(19.4m)(49.9m)(8.7m)(7.2m)(15.1m)2.6m

EBIT margin, %

(94%)(13%)(13%)(11%)(30%)(7%)(7%)(19%)4%

Interest expense

3.7m7.3m783.3k5.6m

Interest income

250.0k50.0k1.4m

Pre tax profit

(17.6m)(13.8m)(51.8m)(3.2m)(10.8m)(18.8m)3.2m

Income tax expense

115.5k33.0k105.0k318.0k(108.0k)86.0k(19.0k)

Net Income

(23.3m)(19.0m)(17.7m)(13.8m)(51.9m)(3.5m)(11.0m)(18.9m)3.2m

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

3.8m4.4m16.6m15.4m18.6m22.6m25.5m25.3m50.2m47.8m41.3m50.5m34.0m42.9m32.9m30.7m26.0m26.2m24.4m26.5m27.1m27.4m18.8m22.3m21.2m

Cost of goods sold

2.5m3.9m12.9m12.9m14.5m14.4m17.6m17.9m32.3m31.1m32.8m26.9m33.0m23.5m27.7m22.2m20.5m19.5m18.6m16.4m18.3m19.0m18.6m15.9m20.6m19.6m

Gross profit

1.3m514.9k3.7m2.5m4.1m8.2m7.9m7.4m17.9m15.0m14.4m17.5m10.5m15.2m10.7m10.2m6.5m7.6m8.0m8.2m8.2m8.8m2.9m1.7m1.5m

Gross profit Margin, %

35%12%22%16%22%36%31%29%36%31%35%35%31%35%33%33%25%29%33%31%30%32%16%8%7%

Sales and marketing expense

2.0m2.6m2.3m4.0m6.3m5.8m7.7m7.2m8.3m7.1m4.3m2.7m1.9m1.9m2.2m2.0m3.7m5.0m3.6m751.0k809.0k574.0k

R&D expense

1.1m1.2m735.5k965.0k921.0k1.4m863.0k531.0k270.0k137.0k152.0k199.0k212.0k208.0k185.0k247.0k215.0k232.0k

General and administrative expense

3.2m2.9m4.4m4.2m7.9m8.9m10.7m1.9m1.9m3.7m5.0m5.1m4.6m4.2m4.4m3.9m2.9m2.8m3.5m2.5m2.7m3.0m2.6m2.4m1.9m

Operating expense total

3.2m2.9m4.4m4.2m7.9m8.9m10.7m12.3m15.4m15.2m19.5m21.7m24.2m37.5m21.0m12.2m11.5m9.1m10.0m9.3m9.1m8.0m9.8m6.2m6.6m5.6m

Depreciation and amortization

100.0k100.0k

EBIT

(1.9m)(2.4m)(727.3k)(1.7m)(3.8m)(721.5k)(2.7m)(4.9m)2.4m479.5k(4.5m)(7.3m)(6.7m)(27.0m)(5.8m)(1.5m)(1.3m)(2.6m)(2.4m)(1.3m)(926.0k)125.0k(991.0k)(3.3m)(4.8m)(4.1m)

EBIT margin, %

(50%)(54%)(4%)(11%)(21%)(3%)(11%)(19%)5%(9%)(18%)(13%)(80%)(13%)(5%)(4%)(10%)(9%)(5%)(3%)0%(4%)(18%)(22%)(19%)

Interest expense

3.0m499.8k2.6m976.7k3.3m780.3k1.1k1.3k39.4k17.0k28.7k183.0k348.0k559.0k

Interest income

18.4k17.0k10.0k222.8k

Pre tax profit

2.8m697.2k(7.5m)(7.0m)(27.6m)(6.5m)(4.2m)(1.4m)(3.1m)(3.1m)(2.1m)(2.2m)(1.0m)(2.0m)(4.5m)(5.9m)(5.0m)

Income tax expense

32.2k(44.8k)94.5k12.0k21.0k71.0k131.0k7.0k28.0k76.0k14.0k69.0k34.0k(3.0k)10.0k26.0k53.0k

Net Income

(7.4m)116.3k(16.0m)6.2m(6.1m)(7.4m)(2.4m)(3.9m)2.7m408.3k602.6k(7.5m)(7.0m)(27.6m)(6.6m)(4.2m)(1.4m)(3.1m)(3.1m)(2.1m)(2.3m)(1.1m)(2.0m)(4.5m)(5.9m)(5.1m)

MusclePharm Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2019FY, 2020

Cash

659.8k5.4m1.0m7.1m4.9m6.2m1.5m2.0m

Accounts Receivable

2.6m3.3m13.7m16.6m22.0m16.7m4.8m7.5m

Prepaid Expenses

534.5k44.7k3.0m1.7m3.7m993.0k1.1m1.3m

Inventories

258.0k15.8m21.1m12.5m8.6m6.5m4.7m1.0m

Current Assets

4.0m4.9m44.5m46.4m47.3m28.8m30.5m12.2m11.9m

PP&E

907.5k1.4m2.6m7.8m6.7m3.2m1.8m216.0k13.0k

Total Assets

5.0m6.8m52.2m66.4m63.8m34.1m33.8m14.5m13.0m

Accounts Payable

9.4m11.7m28.4m27.8m39.7m9.6m11.7m26.2m14.7m

Short-term debt

1.3m4.5m2.6m8.0m3.0m3.0m10.6m11.1m

Current Liabilities

17.7m16.5m32.4m42.8m67.3m38.4m28.5m41.5m32.0m

Long-term debt

307.2k4.5k54.6k146.0k9.2m17.8m951.0k5.4m

Non-Current Liabilities

4.5k

Total Debt

1.6m4.5m2.5m8.2m3.0m3.0m11.5m16.5m

Total Liabilities

18.0m16.5m32.4m43.0m73.8m39.0m46.4m42.5m37.4m

Common Stock

605.9k2.8k9.3k14.0k14.0k14.0k31.0k32.0k

Additional Paid-in Capital

31.6m54.8m103.1m129.1m147.6m156.3m159.6m177.9m178.3m

Retained Earnings

(45.2m)(64.1m)(81.8m)(95.7m)(147.5m)(151.0m)(162.0m)(195.9m)(192.7m)

Total Equity

(13.0m)(9.8m)19.7m23.4m(10.1m)(4.9m)(12.5m)(28.0m)(24.4m)

Debt to Equity Ratio

-0.1 x0.1 x-0.3 x-0.2 x

Debt to Assets Ratio

0.3 x0 x0 x0.1 x

Financial Leverage

-0.4 x-0.7 x2.6 x2.8 x-6.3 x-7 x-2.7 x-0.5 x-0.5 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

517.8k1.3m292.0k634.9k8.5m8.7m5.7m3.3m3.8m2.9m4.8m4.2m3.5m9.1m13.1m5.9m3.0m3.6m4.9m5.1m2.4m1.7m613.0k1.1m1.5m

Accounts Receivable

2.4m3.6m4.5m2.1m4.0m8.0m9.2m10.9m19.6m19.2m23.2m19.0m24.6m15.6m22.3m20.2m15.9m15.2m13.4m13.1m16.9m16.3m16.2m5.5m7.2m5.2m

Prepaid Expenses

382.5k823.3k336.8k204.5k92.0k1.6m1.1m3.4m1.6m2.0m1.8m2.0m3.6m3.4m4.0m4.5m3.0m2.1m2.4m1.9m895.0k1.1m1.1m827.0k697.0k815.0k

Inventories

219.3k396.9k419.4k1.2m9.6m16.7m19.8m24.0m13.9m14.9m19.3m8.6m6.9m8.0m6.1m6.1m6.3m7.7m7.7m7.3m9.8m8.5m7.1m

Current Assets

3.3m4.7m6.4m3.0m5.8m19.0m21.7m34.4m49.0m49.2m59.0m45.8m53.2m45.2m45.2m44.8m32.9m26.6m25.6m26.3m30.8m27.5m26.4m16.8m17.5m14.6m

PP&E

514.4k903.6k1.1m1.3m1.5m1.4m1.3m1.7m5.5m6.2m7.3m7.5m7.6m7.0m6.4m3.9m3.3m2.9m2.5m2.2m1.6m1.5m576.0k433.0k355.0k280.0k

Total Assets

4.9m5.7m7.6m4.7m7.8m20.5m23.3m41.5m65.6m65.6m79.6m67.9m75.1m62.2m61.2m50.6m38.3m31.1m29.8m30.1m33.9m30.4m28.3m20.2m20.5m17.3m

Accounts Payable

2.9m4.7m7.8m5.2m10.1m7.7m8.2m16.5m24.3m23.9m28.1m28.8m37.8m40.4m39.4m39.1m36.1m10.9m9.1m9.4m14.9m16.6m20.7m19.9m24.4m27.9m

Short-term debt

2.0m1.0m1.2m(1.4m)(3.9m)76.7k74.3k70.5k2.6m45.6k8.1m9.3m7.3m5.9m21.0k11.0k11.0k3.9m2.0m2.0m1.5m24.7m25.7m8.2m

Current Liabilities

10.3m10.1m24.5m15.6m14.9m13.3m10.6m18.9m30.7m28.5m41.4m44.2m54.2m67.5m72.6m65.3m53.9m38.1m37.8m22.4m30.4m27.6m28.5m51.2m57.3m40.9m

Long-term debt

87.6k792.9k248.9k114.7k159.2k506.074.3k78.0k177.9k412.0k135.7k2.7m2.7m3.6m227.0k137.0k103.0k270.0k1.9m19.0m18.0m18.3m17.3m1.3m1.1m1.0m

Total Debt

2.1m1.8m1.4m(1.2m)(3.7m)77.2k74.3k148.5k2.5m91.2k91.2k12.1m6.0m2.6m3.0m3.0m3.0m270.0k1.9m22.9m2.0m2.0m1.5m26.0m26.8m9.2m

Total Liabilities

10.4m10.9m24.8m15.7m15.1m13.3m10.6m18.9m30.8m28.8m41.5m46.9m56.9m67.8m73.1m65.6m54.8m38.5m39.8m41.6m48.5m46.0m45.8m52.5m58.4m42.0m

Common Stock

252.6k354.4k1.4m1.4m2.3m6.8k7.8k8.9k10.5k10.8k11.3k14.0k14.0k14.0k14.0k14.0k14.0k14.0k14.0k14.0k14.0k15.0k15.0k15.0k15.0k31.0k

Additional Paid-in Capital

28.5m28.7m42.8m43.0m51.9m79.3m87.1m101.0m115.4m118.3m125.0m134.3m138.6m142.5m152.4m153.5m153.6m156.9m157.4m158.0m159.8m159.9m160.0m159.1m159.5m177.8m

Retained Earnings

(34.3m)(34.2m)(61.2m)(55.0m)(61.1m)(71.5m)(73.9m)(77.8m)(79.1m)(80.0m)(79.4m)(103.1m)(110.2m)(137.8m)(154.1m)(158.3m)(159.8m)(154.1m)(157.3m)(159.4m)(164.3m)(165.3m)(167.3m)(181.4m)(187.3m)(192.4m)

Total Equity

(5.6m)(5.1m)(17.2m)(11.0m)(7.3m)7.2m12.6m22.7m34.8m36.8m38.1m21.0m18.2m(5.5m)(11.9m)(15.0m)(16.4m)(7.4m)(10.0m)(11.5m)(14.6m)(15.6m)(17.5m)(32.4m)(37.8m)(24.6m)

Debt to Equity Ratio

-0.4 x-0.4 x0 x0 x0.1 x0 x0 x0.3 x-0.5 x-0.3 x-0.2 x-0.2 x-0.1 x-0.1 x-0.1 x

Debt to Assets Ratio

0.4 x0.3 x0 x0 x0 x0 x0 x0.1 x0 x0 x0.1 x0.1 x0.1 x0.1 x0.1 x

Financial Leverage

-0.9 x-1.1 x-0.4 x-0.4 x-1.1 x2.8 x1.8 x1.8 x1.9 x1.8 x2.1 x3.2 x4.1 x-11.2 x-5.2 x-3.4 x-2.3 x-4.2 x-3 x-2.6 x-2.3 x-1.9 x-1.6 x-0.6 x-0.5 x-0.7 x

MusclePharm Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2019FY, 2020

Net Income

(23.3m)(19.0m)(17.7m)(13.8m)(51.9m)(3.5m)(11.0m)(18.9m)3.2m

Depreciation and Amortization

171.6k475.3k7.3m2.0m2.8m2.1m1.5m659.0k465.0k

Accounts Receivable

(2.3m)(742.7k)(10.7m)(2.6m)(5.6m)7.3m(4.6m)1.4m(2.9m)

Inventories

(4.5m)5.9m(480.0k)2.1m8.9m3.7m

Accounts Payable

7.6m10.1m23.1m5.0m14.2m(20.8m)2.0m(70.0k)(4.7m)

Cash From Operating Activities

(5.8m)(697.6k)(10.0m)(4.1m)5.5m(15.1m)(5.1m)(6.5m)(868.0k)

Purchases of PP&E

(831.5k)(924.2k)(1.9m)(4.1m)(1.5m)(508.0k)(37.0k)(13.0k)(4.0k)

Cash From Investing Activities

(831.5k)(965.3k)(3.5m)(1.6m)(3.0m)5.4m(37.0k)(13.0k)218.0k

Short-term Borrowings

(2.5m)(14.5m)(3.0m)(535.0k)(3.7m)

Long-term Borrowings

(75.3k)(5.8m)(4.4m)(104.0k)(1.2m)(3.2m)(139.0k)(41.1m)(43.7m)

Dividends Paid

Cash From Financing Activities

7.2m1.0m18.9m1.4m3.7m7.5m6.4m5.7m1.1m

Net Change in Cash

616.1k(659.8k)5.4m(4.4m)6.1m(2.1m)1.3m(785.0k)471.0k

Interest Paid

28.8k501.2k411.4k158.0k527.0k1.6m2.4m1.4m1.4m

Income Taxes Paid

87.4k301.0k77.0k218.0k106.0k77.0k39.0k

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(12.4m)(12.3m)(16.0m)(9.9m)(15.9m)(7.4m)(9.8m)(13.7m)2.7m1.8m2.4m(7.5m)(14.5m)(42.2m)(6.6m)(10.8m)(12.2m)(3.1m)(6.3m)(8.4m)(2.3m)(3.4m)(5.4m)(4.5m)(10.4m)(15.5m)

Depreciation and Amortization

31.4k89.4k89.7k199.8k325.2k161.3k3.8m10.3m1.4m2.8m4.1m607.0k1.3m2.1m647.0k1.2m1.7m420.0k790.0k1.1m387.0k558.0k822.0k196.0k354.0k509.0k

Accounts Receivable

(2.0m)(3.3m)(2.0m)502.2k(1.5m)(4.4m)(5.7m)(7.8m)(5.1m)(4.8m)(9.1m)(2.3m)(8.1m)890.0k(302.0k)952.0k5.1m(1.9m)(120.0k)(753.0k)(443.0k)(71.0k)(454.0k)557.0k(1.2m)1.1m

Inventories

(219.3k)(396.9k)9.0k86.9k(9.6m)(3.2m)(7.4m)7.2m6.2m487.0k2.3m1.4m59.0k2.5m2.5m2.4m(1.3m)(1.2m)(755.0k)3.7m4.8m6.2m

Accounts Payable

1.1m3.0m3.5m867.1k8.2m1.5m2.1m11.1m(2.3m)(2.7m)2.0m719.0k10.1m(14.9m)(591.0k)(1.2m)(4.9m)803.0k530.0k417.0k2.9m5.8m8.4m(5.2m)(527.0k)1.7m

Cash From Operating Activities

(2.6m)(4.1m)1.4m438.0k286.8k(3.2m)(5.2m)(8.0m)(784.8k)539.9k(5.5m)682.0k4.2m7.7m2.4m(686.0k)(486.0k)(1.0m)(1.8m)(2.3m)(232.0k)(39.0k)2.0m(4.8m)(5.3m)(4.2m)

Purchases of PP&E

(324.4k)(771.7k)(305.8k)(544.9k)(899.8k)(216.3k)(307.8k)(825.2k)(1.3m)(2.4m)(3.7m)(257.0k)(851.0k)(1.3m)(50.0k)(378.0k)(459.0k)(27.0k)(14.0k)(73.0k)(86.0k)(13.0k)(13.0k)(13.0k)

Cash From Investing Activities

(324.4k)(771.7k)(305.8k)(579.9k)(934.8k)(234.6k)(353.6k)(2.9m)(1.3m)315.6k(3.5m)(660.0k)(2.3m)(2.9m)(28.0k)5.5m5.4m(27.0k)(14.0k)(73.0k)(86.0k)(13.0k)(13.0k)(13.0k)

Short-term Borrowings

(2.5m)(16.9k)(4.0m)(6.0m)(14.5m)(3.0m)(3.0m)(3.0m)(1.0m)(1.0m)(1.5m)

Long-term Borrowings

(3.3m)(4.1m)(5.2m)(4.4m)(4.4m)(4.4m)(2.9k)(138.0k)(504.0k)(869.0k)(3.0m)(3.0m)(3.0m)(36.0k)(63.0k)(106.0k)(34.0k)(69.0k)(101.0k)(6.4m)(16.7m)(29.3m)

Cash From Financing Activities

3.4m4.8m(478.1k)(266.7k)615.5k11.9m14.2m16.7m(2.9k)(2.5m)6.6m3.8m1.5m(2.3m)(364.0k)1.2m(6.0m)(900.0k)403.0k2.1m(872.0k)(3.7m)(6.4m)3.1m4.1m3.5m

Net Change in Cash

474.1k(43.7k)639.5k(367.8k)(24.9k)8.5m8.7m5.7m(2.1m)(1.6m)(2.5m)3.8m3.2m2.4m2.0m6.0m(1.2m)(1.9m)(1.4m)(65.0k)(1.1m)(3.8m)(4.5m)(1.7m)(1.2m)(774.0k)

Interest Paid

2.5m101.7k265.1k423.7k501.2k410.5k410.8k35.8k52.8k78.8k124.0k270.0k384.0k439.0k926.0k1.2m672.0k1.1m1.8m614.0k1.9m2.7m440.0k562.0k1.2m

Income Taxes Paid

83.5k77.2k240.3k40.0k54.0k57.0k61.0k113.0k206.0k8.0k62.0k86.0k68.0k69.0k173.0k41.0k73.0k

MusclePharm Ratios

USDQ2, 2011

Debt/Equity

-0.4 x

Debt/Assets

0.4 x

Financial Leverage

-0.9 x

MusclePharm Employee Rating

2.325 votes
Culture & Values
2.3
Work/Life Balance
2.4
Senior Management
2.3
Salary & Benefits
2.6
Career Opportunities
2.4
Source
View MusclePharm profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more